NASDAQ:OLMA
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. reported net income of −$162.5M in fiscal 2025. The diluted share count rose 48.1%.Summary generated from Olema Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−36.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+48.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −71 | −107 | −105 | −142 | −179 |
| Net income | −71 | −105 | −97 | −129 | −162 |
| Free cash flow | −52 | −82 | n/a | −105 | n/a |
Recent filings
- 4Insider transaction report
Sep 2, 2026 - 8-KDirector or officer change
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 4Insider transaction report
Jul 27, 2026 - 8-KResults of a shareholder vote
Jun 23, 2026 - 8-KRegulation FD disclosure
May 26, 2026 - 8-KRegulation FD disclosure
May 21, 2026